Loss of ATG4B and ATG4A results in two-stage cell cycle defects in pancreatic ductal adenocarcinoma cells
Journal of Cell Science · 2023
DOI: 10.1242/jcs.260644 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cell Science, 2023. Verfasst von Paalini Sathiyaseelan und 16 weiteren Autor:innen. Beteiligte Einrichtung: Canada's Michael Smith Genome Sciences Centre , BC Cancer, Vancouver, BC, V5Z 1L3, Canada. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Adenocarcinoma, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: CIHR, Pancreas Centre BC, Pancreatic Cancer Action Network.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) exhibits elevated levels of autophagy, which promote tumor progression and treatment resistance. ATG4B is an autophagy-related cysteine protease under consideration as a potential therapeutic target, but it is largely unexplored in PDAC. Here, we investigated the clinical and functional relevance of ATG4B expression in PDAC. Using two PDAC patient cohorts, we found that low ATG4B mRNA or protein expression is associated with worse patient survival outcomes, poorly differentiated PDAC tumors and a lack of survival benefit from adjuvant chemotherapy. In PDAC cell lines, ATG4B knockout reduced proliferation, abolished processing of LC3B (also known as MAP1LC3B), and reduced GABARAP and GABARAPL1 levels, but increased ATG4A levels. ATG4B and ATG4A double knockout lines displayed a further reduction in proliferation, characterized by delays in G1-S phase transition and mitosis. Pro-LC3B accumulated aberrantly at the centrosome with a concomitant increase in centrosomal proteins PCM1 and CEP131, which was rescued by exogenous ATG4B. The two-stage cell cycle defects following ATG4B and ATG4A loss have important therapeutic implications for PDAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Canada's Michael Smith Genome Sciences Centre , BC Cancer, Vancouver, BC, V5Z 1L3, Canada.
- Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, V5A 1S6, Canada.
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, V6T 2B5, Canada.
- School of Population and Public Health , University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
- Pancreas Centre BC, Vancouver, BC, V5Z 1L8, Canada.
- Genetic Pathology Evaluation Centre, Vancouver, BC, V6H 3Z6, Canada.
ORCID-Profile: Steve E Kalloger, Jing Xu, Christine Chow, Gregg B Morin, Sharon M Gorski
Förderung
- CIHR
- Pancreas Centre BC
- Pancreatic Cancer Action Network
- BC Cancer Foundation
- Canadian Institutes of Health Research
Zitieren
APA
Sathiyaseelan, P., Chittaranjan, S., Kalloger, S. E., Chan, J., Go, N. E., Jardon, M. A., Ho, C. J., Hui, T., Xu, J., Chow, C., Gao, D., Johnson, F. D., Lockwood, W. W., Morin, G. B., Renouf, D. J., Schaeffer, D. F., & Gorski, S. M. (2023). Loss of ATG4B and ATG4A results in two-stage cell cycle defects in pancreatic ductal adenocarcinoma cells. Journal of Cell Science. https://doi.org/10.1242/jcs.260644
Vancouver
Sathiyaseelan P, Chittaranjan S, Kalloger SE, Chan J, Go NE, Jardon MA, et al. Loss of ATG4B and ATG4A results in two-stage cell cycle defects in pancreatic ductal adenocarcinoma cells. Journal of Cell Science. 2023. doi:10.1242/jcs.260644
BibTeX
@article{Sathiyaseelan2023,
author = {Sathiyaseelan, Paalini and Chittaranjan, Suganthi and Kalloger, Steve E and Chan, Jennifer and Go, Nancy E and Jardon, Mario A and Ho, Cally J and Hui, Theodore and Xu, Jing and Chow, Christine and Gao, Dongxia and Johnson, Fraser D and Lockwood, William W and Morin, Gregg B and Renouf, Daniel J and Schaeffer, David F and Gorski, Sharon M},
title = {Loss of ATG4B and ATG4A results in two-stage cell cycle defects in pancreatic ductal adenocarcinoma cells},
journal = {Journal of Cell Science},
year = {2023},
doi = {10.1242/jcs.260644}
}
EUVIMED